Donate For Public and Patients Store Search

F051 - Atopic Dermatitis

Saturday, March 2; 9:00 AM - 11:00 AM

Learning Objectives

Following this course, the attendee should be able to:

  • Recognize advances in understanding of pathogenesis of atopic dermatitis.
  • Formulate best practices in patient and family education and counseling.
  • Improve knowledge of traditional and emerging topical and system therapies.

Description

Effectively treating patients with atopic dermatitis yields great rewards for patients, families and providers. This session reviews advances in our understanding of the pathobiology of the disease, reviews treatment guidelines and informs providers of the emerging systemic therapies on the horizon. Discussions of therapeutics will extend beyond treatment guidelines as experienced clinicians will share their treatment pearls they find useful in their toughest pediatric and adult patients.

Disclosures

  • Drucker, Aaron Mark, MD: AbbVie – C(H), O(Grants/Research Funding); Eli Lilly and Company – SP(H); GlaxoSmithKline – O(Grants/Research Funding); Intarcia Therapeutics – C(H); Janssen Pharmaceuticals, Inc – C(H), O(Grants/Research Funding); Kallyope – C(H); Merck & Co., Inc – C(H), O(Grants/Research Funding), SP(H); Novartis – C(H); Novo Nordisk A/S – C(H), O(Grants/Research Funding), SP(H); Pfizer Inc. – C(H); Regeneron – O(Grants/Research Funding); Sanofi – O(Grants/Research Funding); Shire – O(Grants/Research Funding), O(IP); Zafgen – C(H);
  • Eichenfield, Lawrence F., MD: Abbvie – I(Grants/Research Funding); Almirall – C(H); Anacor Pharmaceuticals, Inc. – C(H); Asana BioSciences – Data Safety Monitoring Board(H); Cutanea Life Sciences – C(H); Dermavant Sciences, Inc. – C(H); Dermira – C(H); Dr. Reddy – C(H); DS Laboratories – C(H); Elsevier Inc. – O(IP); Forte – A(H); Galderma Laboratories, L.P. – C(H), I(Fees); Glenmark Pharmaceuticals, Inc. – Data Safety Monitoring Board(H); LEO Pharma, US – C(H), I(Fees); Lilly ICOS LLC – C(H); MatriSys Bioscience – C(H); Medimetriks Pharmaceuticals, Inc. – C(H); Novan – C(H); Pfizer Inc. – C(H), I(Grants/Research Funding); Sanofi/Regeneron – C(H), I(Fees); TopMD – C(SO); Valeant Pharmaceuticals International – C(H); Valeant Pharmaceuticals North America LLC – I(Fees); Verrica Pharmaceuticals Inc – A(SO), C(H), I(Grants/Research Funding); Wiley-Blackwell – O(H);
  • Guttman, Emma, MD, PhD: AbbVie – C(H), I(Grants/Research Funding); Almirall – A(H), C(H), I(Grants/Research Funding); Amgen – C(H), I(Grants/Research Funding); AnaptysBio – I(Grants/Research Funding); Asana Biosciences, LLC – A(H), C(H), I(Grants/Research Funding); Boehringer Ingelheim – A(H), C(H), I(Grants/Research Funding); Cara Therapeutics – A(H), C(H); Celgene Corporation – A(H), C(H), I(Grants/Research Funding); Concert Pharmaceuticals – C(H), I(Grants/Research Funding); DBV Technologies – A(H), C(H); Dermavant Sciences – A(H), I(Grants/Research Funding); Dermira – A(H), C(H), I(Grants/Research Funding); DS Biopharma – C(H), I(Grants/Research Funding); Eli Lilly and Company – A(H), C(H), I(Grants/Research Funding); EMD Serono – C(H); Escalier – A(H), C(H); FLX Bio – C(H); Galderma Research & Development, LLC – A(H), C(H), I(Grants/Research Funding); Glenmark Generics Inc. – A(H), C(H), I(Grants/Research Funding); Incyte Corporation – A(H); Innovaderm Research Inc. – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); Kiniksa Pharmaceuticals, Ltd. – I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – A(H), C(H), I(Grants/Research Funding); Leo Pharma Inc – A(H), C(H), I(Grants/Research Funding); Mitsibushi Pharma – C(H); Novan – A(H), I(Grants/Research Funding); Novartis – A(H), C(H), I(Grants/Research Funding); Pfizer Inc. – A(H), C(H), I(Grants/Research Funding); Ralexar Therapeutics, Inc – I(Grants/Research Funding); Regeneron – A(H), C(H); Regeneron Pharmaceuticals, Inc. – I(Grants/Research Funding); Sanofi – A(H), C(H); Sienna Biopharmaceuticals – A(H), C(H), I(Grants/Research Funding); UCB – I(Grants/Research Funding); Union Therapeutics – C(H), I(Grants/Research Funding);
  • Simpson, Eric Lawrence, MD: AbbVie – C(Fees), I(Grants/Research Funding); Boehringer Ingelheim – C(Fees); Demira – C(Fees); Dermavant Sciences – C(Fees); Eli Lilly and Company – C(Fees), I(Grants/Research Funding); Forte Biosciences – C(Fees); Galderma Laboratories, LP – I(Grants/Research Funding); Incyte Corporation – C(Fees); Kyowa Hakko Kirin Pharma, Inc. – I(Grants/Research Funding); Leo Pharma Inc. – C(Fees), I(Grants/Research Funding); Menlo Therapeutics Inc. – C(Fees); Merck – I(Grants/Research Funding); Pfizer Inc. – C(Fees), I(Grants/Research Funding); Pierre Fabre Dermo Cosmetique France – C(Fees); Regeneron – C(Fees), I(Grants/Research Funding); Sanofi Genzyme – C(Fees); Valeant Pharmaceuticals International – C(Fees);
Schedule
Saturday, March 2
9:00 AM
Dr. Guttman / Pathogenesis
9:30 AM
Dr. Drucker / Comorbidities -- what do derms need to know, do we need to screen or treat?
10:00 AM
Dr. Eichenfield / Topical treatment
10:30 AM
Dr. Simpson / Systemic treatment
Event Details
  • Date
    Saturday, March 2
  • Time
    9:00 AM - 11:00 AM
  • Location
    Ballroom C
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
  • Eric Lawrence Simpson, MD, FAAD
  • Lawrence F. Eichenfield, MD, FAAD
Speakers